• Skip to main content
  • Skip to after header navigation
  • Skip to site footer
ERN: Emerging Researchers National Conference in STEM

ERN: Emerging Researchers National Conference in STEM

  • About
    • About AAAS
    • About the NSF
    • About the Conference
    • Partners/Supporters
    • Project Team
  • Conference
  • Abstracts
    • Undergraduate Abstract Locator
    • Graduate Abstract Locator
    • Abstract Submission Process
    • Presentation Schedules
    • Abstract Submission Guidelines
    • Presentation Guidelines
  • Travel Awards
  • Resources
    • Award Winners
    • Code of Conduct-AAAS Meetings
    • Code of Conduct-ERN Conference
    • Conference Agenda
    • Conference Materials
    • Conference Program Books
    • ERN Photo Galleries
    • Events | Opportunities
    • Exhibitor Info
    • HBCU-UP/CREST PI/PD Meeting
    • In the News
    • NSF Harassment Policy
    • Plenary Session Videos
    • Professional Development
    • Science Careers Handbook
    • Additional Resources
    • Archives
  • Engage
    • Webinars
    • ERN 10-Year Anniversary Videos
    • Plenary Session Videos
  • Contact Us
  • Login

Dipeptidyl Peptidase 4 Inhibitors Augment the Activation of Cardiac Fibroblasts by SDF-1α, Neuropeptide Y, and Peptide YY

Undergraduate #50
Discipline: Biological Sciences
Subcategory: Cell and Molecular Biology

Jasmine Johnson - University of Arkansas at Pine Bluff
Co-Author(s): Delbert G. Gillespie and Edwin K. Jackson, Molecular Pharmacology, SURP, University of Pittsburgh



Dipeptidyl Peptidase 4 (DPP4) inhibitors, for example sitagliptin, are a class of antidiabetic drugs that increase insulin release by blocking the metabolism of incretins, which are insulin releasing hormones. Several randomized controlled clinical trials and observational studies suggest that DPP4 inhibitors increase the risk of heart failure, although the mechanism remains unclear. We hypothesize that DPP4 inhibitors, by blocking the metabolism (inactivation) of peptides such as SDF-1α, neuropeptide Y (NPY), and peptide YY (PYY), stimulate the proliferation of and extracellular matrix production by cardiac fibroblasts (CFs), a process that could induce cardiac fibrosis and dysfunction. To test this concept, we examined whether sitagliptin augments the effects of SDF-1α, NPY, and PYY on cell proliferation (by cell counting), total collagen production (by proline incorporation), and collagen I synthesis (by ELISA) in CFs obtained from genetically hypertensive rats. The results showed that both NPY and PYY augment the proliferation of CFs and that this response is enhanced by sitagliptin. Similar results were obtained with SDF-1α. To date these findings support our hypothesis and suggest that antagonists of SDF-1α receptors (CXCR4) or NPY/PYY receptors (Y1) could improve the clinical safety of DPP4 inhibitors.

Funder Acknowledgement(s): LSAMP, American Society for Pharmacology and Experimental Theurapetics

Faculty Advisor: Annissa Buckner, buckner.ae@gmail.com

Role: I did most of the research in this experiment. I set up the experiment and ran the experiment that only part that I was assisted on was running the samples through the certain instrumentation.

Sidebar

Abstract Locators

  • Undergraduate Abstract Locator
  • Graduate Abstract Locator

This material is based upon work supported by the National Science Foundation (NSF) under Grant No. DUE-1930047. Any opinions, findings, interpretations, conclusions or recommendations expressed in this material are those of its authors and do not represent the views of the AAAS Board of Directors, the Council of AAAS, AAAS’ membership or the National Science Foundation.

AAAS

1200 New York Ave, NW
Washington,DC 20005
202-326-6400
Contact Us
About Us

  • LinkedIn
  • Facebook
  • Instagram
  • Twitter
  • YouTube

The World’s Largest General Scientific Society

Useful Links

  • Membership
  • Careers at AAAS
  • Privacy Policy
  • Terms of Use

Focus Areas

  • Science Education
  • Science Diplomacy
  • Public Engagement
  • Careers in STEM

Focus Areas

  • Shaping Science Policy
  • Advocacy for Evidence
  • R&D Budget Analysis
  • Human Rights, Ethics & Law

© 2023 American Association for the Advancement of Science